Watanabe A, Satoh K
Department of Pediatrics, Aomori Prefectural Central Hospital.
Jpn J Antibiot. 1994 Jul;47(7):882-8.
Biapenem (L-627) was given intravenously to 17 children with acute bacterial infections including 3 with purulent tonsillitis, 1 with bronchitis, 4 with pneumonia, 2 with sepsis, 3 with pyelonephritis, 2 with SSSS. (2 cases are omitted from evaluation because of Mycoplasma pneumonia and infectious mononucleosis). Daily dosages per kg bodyweight ranging from 18.3 to 60 mg were given in 3 divided doses per day for 4 to 6 days. Clinical responses were excellent in 12 (80%), good in 2 (13.3%), fair in 1 (6.7%) and poor in 0 (0%), with an overall efficacy rate of 93.3%. Good bacteriological responses were obtained in all of the 9 cases from which pathogens were identified. A side effect is observed in only 1 case with mild diarrhea. The above results suggest that L-627 is a useful new carbapenem derivative for the treatment of bacterial infections in children.
将比阿培南（L-627）静脉注射给17名患有急性细菌感染的儿童，其中包括3例化脓性扁桃体炎、1例支气管炎、4例肺炎、2例败血症、3例肾盂肾炎、2例葡萄球菌烫伤样皮肤综合征。（2例因支原体肺炎和传染性单核细胞增多症未纳入评估）。每日每千克体重剂量为18.3至60毫克，分3次给药，持续4至6天。临床疗效：优12例（80%），良2例（13.3%），中1例（6.7%），差0例（0%），总有效率为93.3%。在所有9例鉴定出病原体的病例中均获得了良好的细菌学反应。仅1例出现副作用，表现为轻度腹泻。上述结果表明，L-627是一种用于治疗儿童细菌感染的新型有效碳青霉烯类衍生物。
